TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10389787

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with ropivacaine (10 mg/mL, 15-25 mL) followed by an infusion (2 mg/mL, 4-6 mL/h for 24 h, plus top-up doses of 6-10 mL for 48 h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia followed by IV patient-controlled analgesia with morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with ropivacaine
Number of subjects: 90
Study: 8678497

Group type: EXPERIMENTAL
Intervention: IA with a double-lumen reservoir (DR group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: IA with a conventional reservoir (SR group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Reservoir patency
Number of subjects: 99
Study: 1653578

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg die) for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 10
Study: 7080881

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (vodka and tonic, 1:5 ratio, mean blood alcohol level of .064%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol expectancy (placebo beverage: water and tonic, 1:5 ratio)
Number of subjects: 0
Study: 31970898

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT) requiring leaning and reaching, 10-12 sessions of 30-45 minutes each
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group with trunk restrained performing VRT with small upper extremity movements, 10-12 sessions of 30-45 minutes each
Number of subjects: 76
Study: 31233639

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 28571235

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study: 26143402

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study: 24411424

Group type: EXPERIMENTAL
Intervention: Laparoscopic Training Group (n = 9, Group A)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard Training Group (n = 8, Group B)
Number of subjects: 17
Study: 22045156

Group type: EXPERIMENTAL
Intervention: Pregabalin (PG) 300 mg orally before surgery and 150 mg twice a day for 48 hours postoperatively
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregabalin (PG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study: 19252826

Group type: EXPERIMENTAL
Intervention: Selenium intake (greater than the RDA of 55 microg/day)
Number of subjects: 23
Study: 17464604

Group type: COMPARATOR
Intervention: Continuous epidural infusion (group E)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infiltration around the hip joint with a mixture of 100 mL ropivacaine 2 mg/mL, 1 mL ketorolac 30 mg/mL, and 1 mL epinephrine 0.5 mg/mL (group A)
Number of subjects: 80
Study: 15246889

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 12195326

Group type: EXPERIMENTAL
Intervention: Training using the GI-Mentor virtual reality endoscopy simulator for 2 hours per day for 3 weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: No training (control group).
Number of subjects: 24

Group type: COMPARATOR
Intervention: Experts in gastrointestinal endoscopy.
Number of subjects: 24
Study: 11189397

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 7896993

Group type: EXPERIMENTAL
Intervention: Random assignment to day hospital rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random assignment to inpatient rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-selected day hospital rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-selected inpatient rehabilitation
Number of subjects: 0
Study: 1971028

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 367979

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg per day for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg per day for 6 months
Number of subjects: 0
Study: 31110098

Group type: EXPERIMENTAL
Intervention: Concomitant administration of 4CMenB and routine vaccines
Number of subjects: 5026

Group type: COMPARATOR
Intervention: Prior AEFI(s)
Number of subjects: 5026
Study: 28316279

Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban
Number of subjects: 3396

Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 3396

Group type: COMPARATOR
Intervention: Aspirin (100 mg)
Number of subjects: 3396

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3396
Study: 26107519

Group type: EXPERIMENTAL
Intervention: Maternity leave educational tool
Number of subjects: 155
Study: 24325695

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloons (PCB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Uncoated balloons (Control)
Number of subjects: 86
Study: 21521505

Group type: EXPERIMENTAL
Intervention: Rapid result group (PCR assay providing results on the following day)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Delayed result group (PCR assay providing results after eight to twelve days)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Rapid result group
Number of subjects: 406

Group type: COMPARATOR
Intervention: Delayed result group
Number of subjects: 406
Study: 18972894

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 1:400,000 (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline with adrenaline 1:400,000 (group S)
Number of subjects: 50
Study: 16377496

Group type: EXPERIMENTAL
Intervention: Preoperative bowel clearance
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Nasogastric tube management
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Postoperative recovery timeline
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Postoperative ileus
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Length of postoperative hospital stay
Number of subjects: 1082
Study: 12952703

Group type: EXPERIMENTAL
Intervention: JUTE model (Web-based educational model)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control Website (information available on the Internet)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: JUTE model
Number of subjects: 34
Study: 11003448

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 2 years
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 24
Study: 8820893

Group type: EXPERIMENTAL
Intervention: Trial 1 (1690.3 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trial 2 (2529.1 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trial 3 (3384.3 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined trials
Number of subjects: 12
Study: 1419942

Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle with bevel parallel to dural fibers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle with bevel perpendicular to dural fibers
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 300
Study: 3880715

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 80

Group type: COMPARATOR
Intervention: End-to-side portacaval shunt
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both shunts
Number of subjects: 80
Study: 30758912

Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Number of subjects: 830
Study: 29954183

Group type: EXPERIMENTAL
Intervention: Rifampin 10 mg/kg/d
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg/d
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg/d
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All rifampin doses
Number of subjects: 180
Study: 27052839

Group type: EXPERIMENTAL
Intervention: Kinetic Oscillation Stimulation (KOS) with high amplitude pressure (mean pressure of 65 mbar, pressure amplitude of 100 mbar, and 68 Hz)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Kinetic Oscillation Stimulation (KOS) with low amplitude pressure (mean pressure of 65 mbar, pressure amplitude of 4 mbar, and 68 Hz)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Uninflated balloon treatment (control group)
Number of subjects: 207
Study: 25179086

Group type: EXPERIMENTAL
Intervention: Melatonin supplementation (5 mg daily for 90 days)
Number of subjects: 102
Study: 21918912

Group type: EXPERIMENTAL
Intervention: Rapid Motor Imitation Antecedent Training (RMIA) combined with parent education
Number of subjects: 5
Study: 20014913

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17578790

Group type: EXPERIMENTAL
Intervention: Switch to nevirapine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuation of efavirenz therapy
Number of subjects: 52
Study: 15626320

Group type: EXPERIMENTAL
Intervention: 1.5 mg/mL rhBMP-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other concentrations of rhBMP-2
Number of subjects: 0
Study: 11409559

Group type: EXPERIMENTAL
Intervention: 15 ml of bupivacaine 0.5% with epinephrine 0.0005%
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 15 ml of bupivacaine 0.5%
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 5 mg of morphine in 15 ml of isotonic saline solution
Number of subjects: 320

Group type: COMPARATOR
Intervention: 15 ml of isotonic saline solution (control group)
Number of subjects: 320
Study: 9734748

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia group (29 infants)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonanemic control group (26 infants)
Number of subjects: 55
Study: 16856319

Group type: EXPERIMENTAL
Intervention: Pea fiber diet (33 g pea fiber product/10 MJ)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pea fiber added to breakfast (12 g/10 MJ) and lunch (15 g/10 MJ)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pea fiber diet
Number of subjects: 11
Study: 3057399

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31704697

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon graft (QT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Semitendinosus/gracilis hamstring graft (STG)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both graft types
Number of subjects: 99
Study: 29993297

Group type: EXPERIMENTAL
Intervention: Avoidance behavior
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Poor insight
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Not-just-right perception
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Different personality traits
Number of subjects: 317
Study: 26318384

Group type: EXPERIMENTAL
Intervention: SB2
Number of subjects: 584

Group type: COMPARATOR
Intervention: INF
Number of subjects: 584
Study: 26089183

Group type: EXPERIMENTAL
Intervention: Encenicline 0.27 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Encenicline 0.9 mg
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 24008606

Group type: EXPERIMENTAL
Intervention: 50 mg Pycnogenol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 21794974

Group type: EXPERIMENTAL
Intervention: Ex-smokers and current smokers
Number of subjects: 718

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Patients with a history of recurrences
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Patients with multiple tumors
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Patients with a history of intravesical therapy
Number of subjects: 718
Study: 17239987

Group type: EXPERIMENTAL
Intervention: 1320-nm Nd:YAG laser therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (untreated skin)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patient self-assessment surveys
Number of subjects: 46
Study: 14758573

Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11812703

Group type: EXPERIMENTAL
Intervention: Lactated Ringers solution (RL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9% saline solution (SS)
Number of subjects: 42
Study: 9826134

Group type: EXPERIMENTAL
Intervention: Programmed endoscopic monitoring with eventual retreatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group with close monitoring and second endoscopy only upon evidence of recurrent bleeding
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Programmed endoscopic monitoring
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 7925517

Group type: EXPERIMENTAL
Intervention: pimobendan (average 10.3 mg.day‐1, n = 119)
Number of subjects: 242

Group type: COMPARATOR
Intervention: enalapril (average 10.7 mg.day‐1, n = 123)
Number of subjects: 242
Study: 2531972

Group type: EXPERIMENTAL
Intervention: Topically applied local anaesthetic cream (EMLA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1101247

Group type: EXPERIMENTAL
Intervention: Idoxuridine 5% in dimethyl sulphoxide (DMSO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Idoxuridine 40% in dimethyl sulphoxide (DMSO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Idoxuridine (both concentrations)
Number of subjects: 50
Study: 31745762

Group type: COMPARATOR
Intervention: Natural cycles (N group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stimulated cycles (S group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All groups (P, N, S)
Number of subjects: 12
Study: 29743149

Group type: EXPERIMENTAL
Intervention: Internet-delivered exercise, education, and pain coping skills training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Internet-delivered education alone
Number of subjects: 148
Study: 28192673

Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg·day‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26317257

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Any antiplatelet/anticoagulant therapy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: ACE inhibitors/angiotensin II antagonist therapy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Any method to stop smoking, lipid lowering agents, antiplatelet and/or anticoagulation therapy, and any kind of exercise program
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Supervised exercise program and use of cilostazol
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 232
Study: 24340989

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.4 mg/kg/hr rocuronium bromide (esmeron) in group 1 (n = 14)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bolus administration of 0.15 mg/kg/hr esmeron in group 2 (n = 11)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Decurarization with proserin in group 3 (n = 11)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Decurarization with sugammadex in group 4 (n = 10)
Number of subjects: 46
Study: 22025580

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Posture change (sitting to supine)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Posture change
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment
Number of subjects: 2
Study: 18454656

Group type: EXPERIMENTAL
Intervention: Preventive regimen for periodontally healthy subjects
Number of subjects: 112

Group type: COMPARATOR
Intervention: Maintenance program for periodontitis subjects
Number of subjects: 112
Study: 16832022

Group type: EXPERIMENTAL
Intervention: CEE + P
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 4262
Study: 15114087

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath-1H) and low-dose Tacrolimus (Tac)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Tac and steroids protocol
Number of subjects: 40
Study: 11405312

Group type: EXPERIMENTAL
Intervention: Goal-setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goals plus feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 9675658

Group type: EXPERIMENTAL
Intervention: TATA-box variant in the promoter of uridine diphosphate glucuronosyltransferase in patients with Gilbert's syndrome
Number of subjects: 46

Group type: COMPARATOR
Intervention: TATA-box variant in the promoter of uridine diphosphate glucuronosyltransferase in controls
Number of subjects: 46

Group type: COMPARATOR
Intervention: Homozygous controls for the TATA-box variant
Number of subjects: 46
Study: 8015796

Group type: EXPERIMENTAL
Intervention: Surgeons with considerable or average expertise
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 146
Study: 2686919

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Metronidazole/gentamicin
Number of subjects: 67
Study: 1089521

Group type: EXPERIMENTAL
Intervention: aprotinin (Trasylol)
Number of subjects: 164

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 164
Study: 31686255

Group type: EXPERIMENTAL
Intervention: High-power therapeutic ultrasound with neutral gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-power therapeutic ultrasound with 5% lipolytic active caffeine gel (phonophoresis)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (neutral gel)
Number of subjects: 90
Study: 30609988

Group type: EXPERIMENTAL
Intervention: Triage algorithm display using Smart Glasses
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Telemedical contact with senior emergency physician using Smart Glasses
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional triage without technical support (control group)
Number of subjects: 31
Study: 28182252

Group type: EXPERIMENTAL
Intervention: Superfine merino wool ensembles
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard cotton clothing
Number of subjects: 39
Study: 25245113

Group type: EXPERIMENTAL
Intervention: Partners Together in Health (PaTH) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 23863908

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial intervention
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1461
Study: 21779579

Group type: EXPERIMENTAL
Intervention: 67 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 133 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19427574

Group type: EXPERIMENTAL
Intervention: Active cranial electrical stimulation (CES)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham cranial electrical stimulation (CES)
Number of subjects: 38
Study: 16764868

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15572016

Group type: EXPERIMENTAL
Intervention: Turning privilege during bed rest
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 419
Study: 12184352

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of ANCOVA
Number of subjects: 0
Study: 9265993

Group type: EXPERIMENTAL
Intervention: + training in relaxation during both sensitization and challenge phase
Number of subjects: 4

Group type: COMPARATOR
Intervention: − training in relaxation during challenge phase only
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High hypnotic susceptible subjects
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low hypnotic susceptible subjects
Number of subjects: 4
Study: 8324040

Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biofeedback to increase EEG alpha
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biofeedback to decrease EEG alpha
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pseudomeditation control
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All treated subjects
Number of subjects: 45
Study: 3521272

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 225
Study: 31225820

Group type: EXPERIMENTAL
Intervention: CI532 with intraoperative intracochlear electrocochleography (ECochG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CI522 with intraoperative intracochlear electrocochleography (ECochG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECochG monitoring during CI electrode insertion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECochG amplitude changes during insertion
Number of subjects: 15
Study: 28364494

Group type: EXPERIMENTAL
Intervention: Manipulated sleep time (60%-130% of habitual sleep time)
Number of subjects: 50
Study: 27483458

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927